Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,110 GBX | -0.46% | -1.80% | +14.25% |
17/05 | Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial | RE |
16/05 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.25% | 24TCr | |
+32.09% | 69TCr | |
+29.39% | 59TCr | |
-1.34% | 37TCr | |
+20.34% | 33TCr | |
+7.39% | 29TCr | |
-3.03% | 21TCr | |
+10.02% | 21TCr | |
+8.49% | 17TCr | |
-0.52% | 16TCr |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder